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Given the high mortality and morbidity rate of infectious diseases worldwide due to 
increasing antibiotic resistance, their early diagnosis is of crucial importance for 
clinical practice as well as the discrimination between septic and sterile inflammatory 
processes. Currently, in clinics the scintigraphy with radiolabelled autologous white 
blood cells (WBC) is routinely used for imaging of infectious pathologies, but, being 
undirect imaging of infection, it does not allow to distinguish aseptic process from 
inflammation caused by the presence of bacteria. Novel attractive strategies have been 
and are being investigated with the goal to directly target the pathogen, exploiting 
several bacteria characteristics or molecules’ mechanisms of action, and at the same 
time to have a better accurate imaging agent for diagnosis and therapy follow-up. 
However, very few radiopharmaceuticals that seemed to be promising in preclinical 
setting are available in clinical practice. This lack of bacteria-specific 
radiopharmaceuticals in humans is related to several issues to be considered. Among 
main critical factors, we might include the bacterial cells properties that can be 
localized, dispersed or in the form of biofilm, the bacterial mutations occurring over 
time, the amount and location of bacteria, if intracellular or extracellular that influence 
and drive the choice of molecule to radiolabel. Furthermore, other issues concern the 
radiopharmaceutical such as the injected dose and after how long it is injected, the 
imaging time points, the pharmacokinetic and pharmacodynamic, the biological 
activity, the a-pyrogenicity, the effect on bacterial vitality and functions. 
Indeed, different approaches have been developed for bacterial imaging, if target-
driven (bacterial metabolism, antimicrobial compounds, cell wall components, iron 
metabolism), if species-driven (Gram-negative, Gram-positive, others), if isotope-
driven (γ or β emission), but, whatever approach is being considered, there are pros 
and cons in each one. In addition, in the literature, there are numerous published 
studies on bacterial imaging that used several compounds such as amino sugars, 
siderophores, peptides, antibiotics. Some of these also obtained promising and 
encouraging results, but also considerably heterogenous in bacterial strain, infection 
animal model, isotope, compound and time flow of the study. 
In the present thesis, we proposed two different approaches to improve the 
management of infectious diseases. Firstly, we radiolabelled with 99mTc two 
compounds, ciprofloxacin dithiocarbamate and polymyxin B, to directly image 
bacteria in two mouse models of infection, respectively the Teflon cage and “Matrigel-
mediated” infection. Secondly, we tried to get better the radiolabelling procedure of 
WBC that is intensively laborious and time consuming. We tested an alternative of 
HMPAO, called SSS-complex, to radiolabel WBC, but it cannot be considered a valid 
substitute. Then, it was strictly necessary to find an alternative of HES, the 
sedimentation agent into the LeukokitÒ, for commercial needs. Therefore, we tested 
Gelofusine as new sedimentation agent that, then, have been replaced HES, also 
apporting better results in terms of overall diagnostic accuracy. 
This thesis highlights the difficulty of accurately localize bacteria during infective 
process and confirms scintigraphy with radiolabelled WBC as the main diagnostic tool 
in clinical routine. In the meantime, the radiolabelling of WBC with PET isotopes (e.g. 
89Zr, 64Cu) is currently under investigation with the aim to improve the diagnostic 
performance of radiolabelled WBC. The PET imaging has higher spatial resolution and 
sensitivity than SPECT technique, surely improving the quantitative evaluation of 
radioactive signal from pathological tissues in infectious diseases. However, some 
concerns have to be taken into account after the radiolabelling procedure, such as the 
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following: the resulted labelling efficiency and specific activity, if the biological 
functions and chemotactic properties of WBC are preserved, if the used PET isotope is 
toxic for cells, the binding kinetics and the efflux rate from the cells. 
At the moment, imaging bacteria is still a difficult and challenging task because an 
ideal bacteria-specific imaging agent should be highly sensitive and specific, 
quantitative, rapid, stable, safe and easily manufacturable as well as characterized by 
specific biochemical properties (e.g. lipophilicity, metabolic stability, low binding to 
plasma proteins).   
Surely, having standardized protocols, guidelines and consensus documents would 
allow a better comparison between preclinical studies and, eventually, a prediction of 
results in humans. Being able to specifically image bacteria would allow to identify the 
responsive cause of an infection with the goal to improve the management, therapy 
decision-making and follow-up of patients with suspected infectious diseases. Indeed, 
the early detection of the specific pathogen responsible of that infection is still an open 
challenge, but it would be able to guide the choice of the most appropriate antibiotic 
therapy for each patient. 
  
